Abstract
COVID-19 poses a global health crisis, necessitating precise diagnostic methods for timely containment. However, accurately delineating COVID-19 affected regions in Lung CT scans is challenging due to contrast variations and significant texture diversity. In this regard, this study introduces a novel two-stage classification and segmentation CNN approach for COVID-19 lung radiological pattern analysis. A novel Residual-BRNet is developed to integrate boundary and regional operations with residual learning, capturing key COVID-19 radiological homogeneous regions, texture variations, and structural contrast patterns in the classification stage. Subsequently, infectious CT images undergo lesion segmentation in the second stage using the newly proposed RESeg segmentation CNN. The RESeg leverages both average and max-pooling implementations to simultaneously learn region homogeneity and boundary-related patterns. Furthermore, novel pixel attention (PA) blocks are integrated into RESeg to effectively address mildly infected regions. The evaluation of the proposed Residual-BRNet CNN demonstrates promising performance metrics, achieving an accuracy of 97.97%, F1-score of 98.01%, sensitivity of 98.42%, and MCC of 96.81%. Meanwhile, PA-RESeg achieves optimal segmentation performance with an IoU score of 98.43% and a Dice Similarity score of 95.96% of the lesion region. These findings highlight the potential of the proposed diagnosis framework to assist radiologists in identifying and analyzing COVID-19 affected lung regions. The CAD GUI diagnosis tool is provided at https://github.com/PRLAB21/COVID-19-Diagnostic-System.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Nil
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The proposed diagnosis utilized a standardized CT image prepared by the (UESTC-COVID-19) Italian Society of Radiology (SIRM) and China Radiological Center [47].
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
I have strengthened the future direction in conclusion section. Moreover, Dr. Bader Khalid Alshemaimri has been added as the corresponding and principal co-author.
